15,853 Shares in Savara Inc (NASDAQ:SVRA) Purchased by Virtu Financial LLC

Virtu Financial LLC bought a new stake in shares of Savara Inc (NASDAQ:SVRA) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 15,853 shares of the company’s stock, valued at approximately $67,000.

Several other institutional investors also recently bought and sold shares of the company. Vestal Point Capital LP increased its position in shares of Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock worth $34,302,000 after acquiring an additional 1,600,000 shares during the period. Frazier Life Sciences Management L.P. grew its stake in Savara by 103.9% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Nantahala Capital Management LLC increased its holdings in Savara by 198.2% during the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock worth $20,879,000 after purchasing an additional 3,443,541 shares during the period. Charles Schwab Investment Management Inc. raised its position in Savara by 238.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock valued at $3,865,000 after purchasing an additional 642,259 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of Savara by 54.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company’s stock valued at $2,928,000 after buying an additional 242,249 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Savara news, Director Joseph S. Mccracken bought 20,000 shares of Savara stock in a transaction dated Tuesday, November 19th. The stock was acquired at an average cost of $2.95 per share, with a total value of $59,000.00. Following the completion of the acquisition, the director now owns 210,837 shares of the company’s stock, valued at approximately $621,969.15. This represents a 10.48 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Matthew Pauls sold 54,702 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total value of $181,063.62. Following the transaction, the chief executive officer now directly owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. This represents a 3.44 % decrease in their position. The disclosure for this sale can be found here. 5.13% of the stock is currently owned by company insiders.

Savara Stock Performance

NASDAQ SVRA opened at $3.23 on Friday. The firm’s fifty day moving average price is $3.47 and its 200 day moving average price is $3.99. Savara Inc has a 12 month low of $2.82 and a 12 month high of $5.70. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The company has a market capitalization of $554.33 million, a price-to-earnings ratio of -7.51 and a beta of 0.92.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11). On average, sell-side analysts expect that Savara Inc will post -0.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently weighed in on SVRA shares. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Thursday. Evercore ISI reissued an “in-line” rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. HC Wainwright decreased their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, Wells Fargo & Company started coverage on Savara in a report on Friday. They issued an “overweight” rating and a $8.00 target price on the stock. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.86.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.